Sarcoma and Cutaneous Tumors

PV QA 2 - Poster Viewing Q&A 2

MO_21_2470 - Prognostic Factors in Adult Localized Chemotherapy-Sensitive Soft Tissue Sarcoma

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Prognostic Factors in Adult Localized Chemotherapy-Sensitive Soft Tissue Sarcoma
B. J. Ager, S. Scheick, J. D. Gruhl, M. M. Poppe, A. Chalmers, R. L. Randall, K. B. Jones, and Y. J. Hitchcock; University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Purpose/Objective(s): The role of systemic therapy in the definitive management of non-metastatic adult soft tissue sarcoma is evolving. We sought to retrospectively analyze factors associated with overall survival (OS) within a cohort of chemotherapy-sensitive adult soft tissue sarcoma histologies using the National Cancer Database (NCDB).

Materials/Methods: The NCDB was queried from 2004-2012 for adult patients with chemotherapy-sensitive non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) histologies, including undifferentiated soft tissue sarcoma, synovial sarcoma, angiosarcoma, fibrosarcoma, mesenchymal extraskeletal chondrosarcoma, leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, and embryonal sarcoma of the liver. Histologies were chosen based on reported chemotherapy response rates. Exclusions included primary sites in bone, joint, skin, retroperitoneum, heart, or unknown location; clinical stage IV or unknown clinical stage; grade 1; no definitive surgery performed; unknown sequencing of chemotherapy and surgery; unknown receipt of chemotherapy; intraoperative chemotherapy; unknown sequencing of radiotherapy and surgery; or date of last follow-up <3 months from diagnosis. Univariate and multivariate Cox proportional hazards modeling were used to analyze variables that were related to OS.

Results: Identified were 10,359 patients meeting inclusion criteria. Of these, 8,538 (82.4%) received no chemotherapy. Radiotherapy was given in 5,689 (54.9%) patients. On multivariate analysis, adjuvant chemotherapy (HR 1.19, p = 0.02), increasing age (HR 1.39, p < 0.01 for age 45 – 65; HR 2.69, p < 0.01 for age >65), Charlson-Deyo Comorbidity Score (HR 1.23, p < 0.01 for score of 1; HR 1.62, p <0.01 for score ≥ 2), tumor size (HR 1.34, p = 0.01 for >2 – 5 cm; HR 2.06, p < 0.01 for >5 – 10 cm; HR 3.22, p < 0.01 for >10 – 15 cm; HR 3.72, p < 0.01 for >15 cm), grade (HR 1.80, p < 0.01 for poorly differentiated; HR 1.85, p <0.01 for undifferentiated), positive margins (HR 1.53, p < 0.01 for R1; HR 2.59, p <0.01 for R2; HR 1.58, p < 0.01 for positive margin not otherwise specified), clinical stage III (HR 1.18, p = 0.02), and angiosarcoma histology (HR 1.81, p < 0.01) were associated with worse OS. Improved OS was associated with neoadjuvant chemotherapy (HR 0.84, p = 0.04), female gender (HR 0.84, p < 0.01), radiotherapy (HR 0.78, p < 0.01 for preoperative; HR 0.68, p < 0.01 for postoperative; HR 0.66, p = 0.02 for pre- and postoperative), liposarcoma histology (HR 0.58, p < 0.01) and undifferentiated pleomorphic sarcoma histology (HR 0.85, p = 0.01).

Conclusion: Prognostic factors for adult non-metastatic, chemotherapy-sensitive NRSTS were identified from a large modern patient cohort within the NCDB. Both neoadjuvant chemotherapy and radiotherapy, given pre- and/or postoperatively, were associated with a significant OS benefit.

Author Disclosure: B.J. Ager: None. S. Scheick: None. M.M. Poppe: Investor; PEEL Therapeutics. Member; Accreditation Council for Graduate Medical Educati. A. Chalmers: None. R.L. Randall: Consultant; Zimmer Biomet, Daiichi Sankyo, Eli Lilly Company, Musculoskeletal Tumor Foundation. Y.J. Hitchcock: None.

Bryan Ager, MD

University of Utah Huntsman Cancer Institute

Presentation(s):

Send Email for Bryan Ager


Assets

MO_21_2470 - Prognostic Factors in Adult Localized Chemotherapy-Sensitive Soft Tissue Sarcoma



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prognostic Factors in Adult Localized Chemotherapy-Sensitive Soft Tissue Sarcoma